Literature DB >> 33049056

Risk-assessment models for VTE and bleeding in hospitalized medical patients: an overview of systematic reviews.

Andrea J Darzi1, Allen B Repp2, Frederick A Spencer3, Rami Z Morsi4, Rana Charide4, Itziar Etxeandia-Ikobaltzeta1, Kenneth A Bauer5, Allison E Burnett6, Mary Cushman2,7, Francesco Dentali8, Susan R Kahn9,10, Suely M Rezende11, Neil A Zakai2,7, Arnav Agarwal1,12, Samer G Karam1, Tamara Lotfi1, Wojtek Wiercioch1, Reem Waziry13, Alfonso Iorio1,3, Elie A Akl1,4,14, Holger J Schünemann1,3.   

Abstract

Multiple risk-assessment models (RAMs) for venous thromboembolism (VTE) in hospitalized medical patients have been developed. To inform the 2018 American Society of Hematology (ASH) guidelines on VTE, we conducted an overview of systematic reviews to identify and summarize evidence related to RAMs for VTE and bleeding in medical inpatients. We searched Epistemonikos, the Cochrane Database, Medline, and Embase from 2005 through June 2017 and then updated the search in January 2020 to identify systematic reviews that included RAMs for VTE and bleeding in medical inpatients. We conducted study selection, data abstraction and quality assessment (using the Risk of Bias in Systematic Reviews [ROBIS] tool) independently and in duplicate. We described the characteristics of the reviews and their included studies, and compared the identified RAMs using narrative synthesis. Of 15 348 citations, we included 2 systematic reviews, of which 1 had low risk of bias. The reviews included 19 unique studies reporting on 15 RAMs. Seven of the RAMs were derived using individual patient data in which risk factors were included based on their predictive ability in a regression analysis. The other 8 RAMs were empirically developed using consensus approaches, risk factors identified from a literature review, and clinical expertise. The RAMs that have been externally validated include the Caprini, Geneva, IMPROVE, Kucher, and Padua RAMs. The Padua, Geneva, and Kucher RAMs have been evaluated in impact studies that reported an increase in appropriate VTE prophylaxis rates. Our findings informed the ASH guidelines. They also aim to guide health care practitioners in their decision-making processes regarding appropriate individual prophylactic management.
© 2020 by The American Society of Hematology.

Entities:  

Mesh:

Year:  2020        PMID: 33049056      PMCID: PMC7556144          DOI: 10.1182/bloodadvances.2020002482

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  55 in total

1.  An electronic tool for venous thromboembolism prevention in medical and surgical patients.

Authors:  Meyer-Michel Samama; Ola E Dahl; Patrick Mismetti; Daniel J Quinlan; Nadia Rosencher; Marleen Cornelis; Han de Vries; Ineke van Beusekom; James P Kahan
Journal:  Haematologica       Date:  2006-01       Impact factor: 9.941

Review 2.  Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients.

Authors:  Alexander T Cohen; Raza Alikhan; Juan I Arcelus; Jean-François Bergmann; Sylvia Haas; Geno J Merli; Alex C Spyropoulos; Victor F Tapson; Alexander G G Turpie
Journal:  Thromb Haemost       Date:  2005-10       Impact factor: 5.249

3.  A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score.

Authors:  S Barbar; F Noventa; V Rossetto; A Ferrari; B Brandolin; M Perlati; E De Bon; D Tormene; A Pagnan; P Prandoni
Journal:  J Thromb Haemost       Date:  2010-11       Impact factor: 5.824

4.  Validation of the International Medical Prevention Registry on Venous Thromboembolism Bleeding Risk Score.

Authors:  David C Hostler; Elizabeth S Marx; Lisa K Moores; Sarah K Petteys; Jordanna Mae Hostler; Joshua D Mitchell; Paul R Holley; Jacob F Collen; Brian E Foster; Aaron B Holley
Journal:  Chest       Date:  2016-01-12       Impact factor: 9.410

5.  Venous thromboembolism risk stratification in medically-ill hospitalized cancer patients. A comprehensive cancer center experience.

Authors:  H N Abdel-Razeq; S B Hijjawi; S G Jallad; B A Ababneh
Journal:  J Thromb Thrombolysis       Date:  2010-10       Impact factor: 2.300

6.  American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients.

Authors:  Holger J Schünemann; Mary Cushman; Allison E Burnett; Susan R Kahn; Jan Beyer-Westendorf; Frederick A Spencer; Suely M Rezende; Neil A Zakai; Kenneth A Bauer; Francesco Dentali; Jill Lansing; Sara Balduzzi; Andrea Darzi; Gian Paolo Morgano; Ignacio Neumann; Robby Nieuwlaat; Juan J Yepes-Nuñez; Yuan Zhang; Wojtek Wiercioch
Journal:  Blood Adv       Date:  2018-11-27

7.  Risk factors for deep vein thrombosis in inpatients aged 65 and older: a case-control multicenter study.

Authors:  Sébastien Weill-Engerer; Sylvie Meaume; Amina Lahlou; François Piette; Olivier Saint-Jean; Annick Sachet; Jean-Yves Beinis; Claude Gallinari; Anne-Sophie Grancher; Jean-Pierre Vincent; Henri Naga; Joel Belmin; Rosella Salvatore; Marie Kazes; Eric Pautas; André Boiffin; Jean-Bernard Piera; Monique Duviquet; David Knafo; Andrée Piau; Dragoslav Miric; Alain Jean; Valérie Bellamy; Olivier Tissandier; Alain-Ferdinand Le Blanche
Journal:  J Am Geriatr Soc       Date:  2004-08       Impact factor: 5.562

8.  Venous thrombosis risk assessment in medical inpatients: the medical inpatients and thrombosis (MITH) study.

Authors:  N A Zakai; P W Callas; A B Repp; M Cushman
Journal:  J Thromb Haemost       Date:  2013-04       Impact factor: 5.824

9.  Validation of a venous thromboembolism risk assessment model in hospitalized chinese patients: a case-control study.

Authors:  Haixia Zhou; Lan Wang; Xiaoling Wu; Yongjiang Tang; Jing Yang; Bo Wang; Yu Yan; Binmiao Liang; Ke Wang; Xuemei Ou; Maoyun Wang; Yulin Feng; Qun Yi
Journal:  J Atheroscler Thromb       Date:  2013-12-03       Impact factor: 4.928

10.  The IMPROVEDD VTE Risk Score: Incorporation of D-Dimer into the IMPROVE Score to Improve Venous Thromboembolism Risk Stratification.

Authors:  C Michael Gibson; Alex C Spyropoulos; Alexander T Cohen; Russell D Hull; Samuel Z Goldhaber; Roger D Yusen; Adrian F Hernandez; Serge Korjian; Yazan Daaboul; Alex Gold; Robert A Harrington; Gerald Chi
Journal:  TH Open       Date:  2017-06-28
View more
  4 in total

Review 1.  Epidemiology and prevention of venous thromboembolism.

Authors:  Pamela L Lutsey; Neil A Zakai
Journal:  Nat Rev Cardiol       Date:  2022-10-18       Impact factor: 49.421

2.  Evaluation of the Padua Prediction Score ability to predict venous thromboembolism in Israeli non-surgical hospitalized patients using electronic medical records.

Authors:  O Lavon; T Tamir
Journal:  Sci Rep       Date:  2022-04-12       Impact factor: 4.379

3.  Safety and effectiveness of thromboprophylaxis use in hospitalized elderly medical patients at a Saudi tertiary care center.

Authors:  Ghazwa B Korayem; Omar A Alshaya; Norah S Alsubaie; Dalal A Alabdulkarim; Omar A Almohammed; Osamah M Alfayez; Majed S Al Yami
Journal:  Saudi Pharm J       Date:  2021-04-28       Impact factor: 4.330

4.  American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19.

Authors:  Adam Cuker; Eric K Tseng; Robby Nieuwlaat; Pantep Angchaisuksiri; Clifton Blair; Kathryn Dane; Jennifer Davila; Maria T DeSancho; David Diuguid; Daniel O Griffin; Susan R Kahn; Frederikus A Klok; Alfred Ian Lee; Ignacio Neumann; Ashok Pai; Menaka Pai; Marc Righini; Kristen M Sanfilippo; Deborah Siegal; Mike Skara; Kamshad Touri; Elie A Akl; Imad Bou Akl; Mary Boulos; Romina Brignardello-Petersen; Rana Charide; Matthew Chan; Karin Dearness; Andrea J Darzi; Philipp Kolb; Luis E Colunga-Lozano; Razan Mansour; Gian Paolo Morgano; Rami Z Morsi; Atefeh Noori; Thomas Piggott; Yuan Qiu; Yetiani Roldan; Finn Schünemann; Adrienne Stevens; Karla Solo; Matthew Ventresca; Wojtek Wiercioch; Reem A Mustafa; Holger J Schünemann
Journal:  Blood Adv       Date:  2021-02-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.